Restorative Parkinson Unit
21 – 40 of 120
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Time to workforce exit after a Parkinson's disease diagnosis
(
- Contribution to journal › Article
-
Mark
Levodopa Dose Equivalency in Parkinson's Disease : Updated Systematic Review and Proposals
(
- Contribution to journal › Article
-
Mark
Agreement between Parkinson Disease Home Diary and Observer Assessments before and after Structured Patient Training
(
- Contribution to journal › Article
-
Mark
The Relationship between PDQ-8 and Costs in Parkinson's Disease—A Swedish Register-Based Study
(
- Contribution to journal › Article
-
Mark
Clinical Impression of Severity Index for Parkinson's Disease and Its Association to Health-Related Quality of Life
(
- Contribution to journal › Article
-
Mark
The Impact of COVID-19 on Parkinson's Disease : A Case-Controlled Registry and Questionnaire Study on Clinical Markers and Patients' Perceptions
(
- Contribution to journal › Article
-
Mark
Tumoral parkinsonism—Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment
(
- Contribution to journal › Scientific review
-
Mark
Patient perspective in hereditary ataxia
(
- Contribution to journal › Published meeting abstract
-
Mark
Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration
(
- Contribution to journal › Article
-
Mark
Agreement Between Parkinson Disease Home Diary and Observer Assessments Before and After Structured Patient Training
2023) 2023 International Congress of The Parkinson and Movement Disorder Society(
- Contribution to conference › Abstract
- 2022
-
Mark
Quality of life and resource utilization-Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study
(
- Contribution to journal › Article
-
Mark
Gait and balance among people with de novo vs. mild to moderate Parkinson’s disease
2022) 6th International Conference on Neurology and Brain Disorders (Virtual)(
- Contribution to conference › Abstract
-
Mark
Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson’s disease
(
- Contribution to journal › Article
-
Mark
Safinamide in the treatment pathway of Parkinson’s Disease : a European Delphi Consensus
(
- Contribution to journal › Article
-
Mark
Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain : rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial
(
- Contribution to journal › Article
-
Mark
Objective Observer vs. Patient Motor State Assessments Using the PD Home Diary in Advanced Parkinson's Disease
(
- Contribution to journal › Article
-
Mark
Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease : Real-World Evidence From G7 Countries
(
- Contribution to journal › Article
-
Mark
Caregiver Burden and Quality of Life in Late Stage Parkinson’s Disease
(
- Contribution to journal › Article
-
Mark
Does the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countries
(
- Contribution to journal › Article
-
Mark
Insights on Genetic and Environmental Factors in Parkinson's Disease from a Regional Swedish Case-Control Cohort
(
- Contribution to journal › Article